Equities researchers at HC Wainwright assumed coverage on shares of Pulmatrix (NASDAQ:PULM) in a research report issued on Friday, MarketBeat reports. The firm set a “buy” rating and a $5.00 price target on the biotechnology company’s stock. HC Wainwright’s target price indicates a potential upside of 231.13% from the stock’s previous close.

Separately, ValuEngine raised Pulmatrix from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd.

Shares of Pulmatrix (NASDAQ PULM) opened at $1.51 on Friday. Pulmatrix has a 1 year low of $1.35 and a 1 year high of $5.10.

Pulmatrix (NASDAQ:PULM) last posted its earnings results on Thursday, November 9th. The biotechnology company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.08. The business had revenue of $0.34 million during the quarter. analysts forecast that Pulmatrix will post -1 EPS for the current fiscal year.

A hedge fund recently raised its stake in Pulmatrix stock. Vanguard Group Inc. raised its position in shares of Pulmatrix Inc (NASDAQ:PULM) by 8.0% in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 99,758 shares of the biotechnology company’s stock after purchasing an additional 7,351 shares during the quarter. Vanguard Group Inc. owned about 0.52% of Pulmatrix worth $240,000 as of its most recent SEC filing. 19.95% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Pulmatrix (PULM) Coverage Initiated at HC Wainwright” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.thecerbatgem.com/2018/02/11/pulmatrix-pulm-coverage-initiated-at-hc-wainwright.html.

About Pulmatrix

Pulmatrix, Inc is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company’s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis.

Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.